Introduction
Ravulizumab, impaired neuromuscular transmission, autoimmune disease, complement-associated disorders
AUTOIMMUNE DISEASE, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Myasthenia gravis (MG) is a rare, chronic, debilitating autoimmune disease arising from impaired neuromuscular transmission [The majority of patients (~ 85%) with gMG have autoantibodies directed against the postsynaptic acetylcholine receptor (AChR); binding of these autoantibodies has been shown to activate the classical complement cascade [Ravulizumab is a humanized monoclonal antibody that specifically binds with high affinity to the human terminal complement protein C5 [Phase 3 studies in patients with complement-associated disorders (paroxysmal nocturnal hemoglobinuria [Most recently, ravulizumab has demonstrated rapid, sustained efficacy and good tolerability in patients with AChR Ab+ gMG in the randomized, placebo-controlled period (RCP) of the phase 3 CHAMPION MG study [